dm+d

441758000

New Medicines

FirmagonHigh risk localised and locally advanced hormone dependent prostate cancer - neoadjuvant therapy in combination with radiotherapy

Information

Firmagon
Licence extension / variation
Ferring
Ferring

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A selective gonadotrophin releasing hormone (GnRH) antagonist. Given in a starting dose of 240mg (as two consecutive injections of 120mg) followed by a maintenance dose of 80mg on days 28 and 56.
The age-standardised incidence of prostate cancer in England in 2016 was 173.7 per 100,000 in 2016 [1].
High risk localised and locally advanced hormone dependent prostate cancer - neoadjuvant therapy in combination with radiotherapy
Subcutaneous injection

FirmagonPrevention of cardiovascular events in men with advanced prostate cancer

Information

Firmagon
Licence extension / variation
Ferring
Ferring

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A selective gonadotrophin releasing hormone (GnRH) antagonist
In the UK, prostate cancer (PC) is the most common cancer in men, with approximately 45,400 diagnoses and 10,600 deaths attributed to PC in 2012. Additionally, men with PC represent a high-risk population for cardiovascular disease, with many of the risk factors for PC being associated with high risk of CVD (e.g. obesity, diet, sedentary lifestyle). The commonest non-PC cause of death in such men is CVD [3].
Prevention of cardiovascular events in men with advanced prostate cancer
Subcutaneous injection